跳转至内容
Merck
CN

SML4248

BIIB021

≥98% (HPLC), powder, Hsp90 inhibitor

别名:

6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9H-purin-2-amine, 6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9Hpurin-2-ylamine, [6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-yl]amine, BIIB 021, BIIB-021, CNF 2024, CNF-2024,CNF2024

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C14H15ClN6O
化学文摘社编号:
分子量:
318.76
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

General description

BIIB021 is a purine scaffold-based second-generation heat shock protein 90 (Hsp90) inhibitor.

Application

BIIB021 may be used to study its effect on growth of natural killer (NK) cells and T cell lymphomas.

Biochem/physiol Actions

BIIB021 (CNF2024) is an orally active, potent and selective heat shock protein 90 (Hsp90) inhibitor that targets the ATP site of Hsp90 (Ki = 1.7 nM against 2 nM FITC-geldanamycin in competitive binding for 0.8 nM rhHsp90α), but not those of 20 cellular kinases or Na+/K+ ATPase. BIIB021 induces Her-2 degradation in MCF7 cells (IC50 = 38 nM post 16h incubation) and exhibits anti-cancer efficacy in cultures (IC50 = 60-310 nM among 8 cancer lines) and in mice in vivo (51-94% tumor growth inhibition among 6 human tumor models; 75-125 mg/kg/d 5x per wk for 5 wks).

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Srinivas R Kasibhatla et al.
Journal of medicinal chemistry, 50(12), 2767-2778 (2007-05-10)
Heat shock protein 90 (Hsp90) is a molecular chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins. Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their
Karen Lundgren et al.
Molecular cancer therapeutics, 8(4), 921-929 (2009-04-18)
Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy. BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that
Boris Böll et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(16), 5108-5116 (2009-08-13)
In Hodgkin's lymphoma, constitutive activation of NF-kappaB promotes tumor cell survival and proliferation. The molecular chaperone heat shock protein 90 (HSP90) has immune regulatory activity and supports the activation of NF-kappaB in Hodgkin's lymphoma cells. We analyzed the effect of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持